Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Massachusetts Eye Research and Surgery Institute (MERSI) is a world-renowned clinical and research center specializing in ocular inflammatory diseases, uveitis, and complex ophthalmic surgeries. Founded by Dr. C. Stephen Foster, the institute is a leader in the use of systemic immunomodulatory therapy to treat vision-threatening conditions that do not respond to conventional treatments. MERSI serves as a tertiary referral center, attracting patients globally for its expertise in managing rare diseases such as ocular cicatricial pemphigoid and birdshot chorioretinopathy. In addition to its clinical practice, MERSI is a highly active clinical research site, conducting numerous Phase 1 through Phase 4 trials for innovative pharmaceutical and biotech companies. The institute is also deeply committed to education, offering fellowships and collaborating with the Ocular Immunology and Uveitis Foundation to advance the field of ocular immunology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Massachusetts Eye Research and Surgery Institute.